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BRIEF REPORT
Proatherogenic Cytokine Microenvironment in the Aortic Adventitia of Patients
With Rheumatoid Arthritis
Ammad Ahmed,1 Ivana Hollan,2 Samuel A. Curran,1 Susan M. Kitson,1 Marcello P. Riggio,1 Knut Mikkelsen,2
Sven M. Almdahl,3 Pa˚l Aukrust,4 Iain B. McInnes,1 and Carl S. Goodyear1
Objective. Patients with rheumatoid arthritis
(RA) are at increased risk of developing cardiovascular
disease (CVD) via mechanisms that have not yet been
defined. Inflammatory pathways, in particular within
the vascular adventitia, are implicated in the pathogen-
esis of primary CVD but could be amplified in RA at the
local tissue level. The aim of this study was to examine
the aortic adventitia of coronary artery disease (CAD)
patients with or without RA to determine the cytokine
profile contained therein.
Methods. Aortic adventitia and internal tho-
racic artery biopsy specimens obtained from 19 RA pa-
tients and 20 non-RA patients undergoing coronary
artery bypass graft surgery were examined by immu-
nohistochemistry.
Results. Interleukin-18 (IL-18), IL-33, and tumor
necrosis factor (TNF) were expressed in aortic adventi-
tia biopsy specimens from both groups, and expres-
sion of these cytokines was significantly higher in RA
patients. In RA patients, IL-33 expression in endothel-
ial cells correlated positively with the number of swollen
joints, suggesting a link between the systemic disease
state and the local vascular tissue microlesion.
Conclusion. The presence of the proinflamma-
tory cytokines IL-18, IL-33, and TNF may play a role in
the inflammatory process within the adventitia that
contributes to plaque formation and destabilization. In
theory, the amplified expression of these cytokines may
contribute to the known increased occurrence and severity
of CAD in patients with RA.
Rheumatoid arthritis (RA) is associated with an
increased risk of cardiovascular disease (CVD), which
cannot be completely explained by traditional risk fac-
tors (1). Cardiovascular events in patients with RA are
characterized by greater severity in terms of recurrence
and mortality. It is likely that both increased plaque for-
mation and plaque vulnerability play roles in the
increased CVD morbidity in patients with RA.
The proposed mechanisms of initiation and per-
petuation of RA as well as atherosclerosis are multifac-
torial and have yet to be fully elucidated. Both diseases
share immunologic/inflammatory components in their
postulated pathology. Inflammation plays an important
role in all stages of the atherosclerotic process (from
endothelial cell [EC] activation to plaque formation,
destabilization, and thrombosis) (2). Levels of systemic
inflammatory biomarkers, including C-reactive protein
(CRP), tumor necrosis factor (TNF), and interleukin-18
(IL-18), predict CVD and/or disease progression in
the general population. Consequently, there has been
increasing interest in the role of cytokines in vascular dis-
ease, and the systemic levels of many cytokines, includ-
ing IL-33, have been investigated in this context. It
should be recognized, however, that the role of circulat-
ing IL-33 is complicated and thought to be situation
dependent.
In mouse models of RA, administration of exoge-
nous IL-33 enhances disease activity, while in models of
atherosclerosis it is protective (3–5). Moreover, the
receptor for IL-33, soluble ST2, is emerging as a novel
biomarker of adverse vascular outcome. Administration
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of excess soluble ST2 has been shown to exacerbate
atherosclerosis in mice (3), suggesting that expression of
circulating IL-33 in the local lesion may indeed be
protective.
We previously reported that among patients with
CVD, those with inflammatory rheumatic diseases have
a higher frequency of inflammatory infiltrates in their
aortic adventitia (6). Furthermore, compared with the
occurrence of inflammatory infiltrates in the aorta, the
occurrence of the adventitial infiltrates was significantly
lower in the internal thoracic artery, which is a vessel
that is highly resistant to atherosclerosis. Adventitial
inflammation involving the vasa vasorum may play a sub-
stantial role in plaque formation, progression, and desta-
bilization and contribute to the increased CV risk in RA.
Consistent with this notion, current research has indicat-
ed a reduction in CV morbidity or mortality in patients
who are treated effectively with antirheumatic therapies,
which might be at least partially mediated through inhi-
bition of vascular inflammation. In support of this con-
cept, a recent study demonstrated significant attenuation
of vascular inflammation in RA patients who received
anti-TNF therapy (7). Thus, with the introduction of
new immunologic therapies, it is essential to examine
which immune factors are involved in the vascular
inflammatory process, because this may have implica-
tions for prevention and treatment of CVD.
We hypothesized that there is an amplified cyto-
kine milieu within vascular lesions in patients with RA
compared with controls, thus providing a potential tissue-
based explanation for the accelerated vascular risk in RA.
Therefore, the aim of this study was to examine inflamma-
tory cytokines that have plausible bioeffects in the vascu-
lature in the aortic adventitia of CVD patients with or
without RA and to evaluate their relationship to informa-
tive clinical parameters. We elected to focus on IL-18,
IL-33, and TNF, because these cytokines have been impli-
cated in the pathology of both atherosclerosis and RA.
Table 1. Characteristics of the patients*
Characteristic RA (n5 19) Non-RA (n5 20) P
Age, years 696 9.1 686 9.5 0.70
Male, no. (%) 12 (63) 14 (70) 0.74
Duration of CAD, years 6.36 8.7 7.26 6.6 0.39
History of myocardial infarction, no. (%) 15 (79) 9 (45) 0.05
Acute coronary syndrome, no. (%) 9 (47) 4 (20) 0.10
Time from angiography to CABG, days 176 30 316 60 0.99
Left ventricular ejection fraction 596 13 646 13 0.16
Hypertension, no. (%) 13 (68) 9 (45) 0.20
Family history of CAD, no. (%) 11 (58) 20 (100) 0.001
Hyperlipidemia, no. (%) 16 (84) 20 (100) 0.11
Duration of RA, years 196 15 – –
Patient’s global assessment of IRD (0–100-mm VAS) 296 24 – –
No. of swollen joints (28 assessed) 2.26 2.6 0 0.002
Disease Activity Score in 28 joints 3.26 1.0 – –
Rheumatoid factor, IU/ml 3166 568 – –
CCP, units/ml 5536 667 – –
C-reactive protein, mg/liter 206 39 3.16 3.1 0.02
ESR, mm/hour 346 29 156 9.5 0.06
Body mass index, kg/m2 256 5.0 256 2.4 0.78
Diabetes, no. (%) 2 (11) 1 (5) 0.61
Previous smoker, no. (%) 10 (52) 12 (60) 0.75
Current smoker, no. (%) 2 (11) 1 (5) 0.61
Current treatment, no. (%)
Oral corticosteroids 8 (42) 0 (0) 0.001
Disease-modifying drugs 16 (84) 0 (0) ,0.0001
COX-2–selective inhibitors 5 (26) 0 (0) 0.02
Traditional NSAIDs 2 (11) 0 (0) 0.23
Lipid-lowering drugs 16 (84) 19 (95) 0.34
Acetylsalicylic acid 17 (90) 17 (85) 1.0
Beta-blockers 15 (88) 14 (74) 0.41
ACE inhibitors 5 (31) 5 (25) 0.47
* Fisher’s unconditional exact test was used to assess differences in proportions between the 2 groups. Differences in continu-
ous variables between the 2 groups were assessed by t-test for independent samples (age, body mass index), Mann-Whitney U
test (duration of coronary artery disease [CAD], time from angiography to coronary artery bypass graft [CABG], left ventricu-
lar ejection fraction, erythrocyte sedimentation rate [ESR]), and Wilcoxon’s signed rank test (no. of swollen joints). Except
where indicated otherwise, values are the mean6 SD. RA5 rheumatoid arthritis; IRD5 inflammatory rheumatic disease;
VAS5 visual analog scale; CCP5 cyclic citrullinated peptide; COX-25 cyclooxygenase 2; NSAIDs5 nonsteroidal antiinflam-
matory drugs; ACE5 angiotensin-converting enzyme.
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PATIENTS AND METHODS
Patients. Among patients undergoing coronary artery
bypass graft (CABG) surgery in the Feiring Biopsy Heart Study
(6), we selected 19 patients who fulfilled the American College
of Rheumatology 1987 revised criteria for the classification of
RA (8) and 20 random control subjects. All of the patients
gave written informed consent. The regional Ethics Committee
for Medical Research Norway approved the study. The demo-
graphic and clinical characteristics of the patients are shown in
Table 1.
Biopsy and immunohistochemistry. We examined
specimens from the aortic adventitia (including the aortic por-
tion of the epicardial layer) and the internal thoracic artery,
which were removed during CABG surgery. A section from the
aortic adventitia (;5 3 10 mm) covered by the periaortic por-
tion of the epicardium was removed from the ventral aspect of
the ascending aorta, in connection with the establishment
of the proximal aortocoronary anastomoses (6). For the safety of
the patients, these anastomoses are made in (and, therefore, the
biopsy specimens are obtained from) areas with less pronounced
atherosclerosis. A section of tissue from the internal thoracic
artery (5–10 mm long) was obtained from the distal portion of
the internal thoracic artery, while the proximal portion was used
as a graft (9). The biopsy specimens were fixed in formalin,
embedded in paraffin, and cut in 3-mm–thick sections. Some
findings regarding the aortic adventitia and internal thoracic
artery used in this study have been reported previously (6,9).
Immunohistochemical analysis. Slides were prepared
as previously described (6). Briefly, depending on the antibody
(additional information is available upon request from the cor-
responding author), slides were preblocked with 0.5% hydro-
gen peroxide followed by antigen retrieval (using the heat-
induced citrate antigen retrieval or trypsin antigen retrieval
protocol). After blocking with 5% normal horse serum with or
without biotin, tissue sections were incubated with primary
antibodies (CD68, IL-18, IL-33, and TNF) overnight, followed
by 0.5% hydrogen peroxide if required. Horseradish peroxi-
dase–conjugated or biotin-conjugated secondary antibodies
were incubated for 1 hour, followed by avidin–biotin-peroxi-
dase complex macromolecular complex (Vector). Binding was
visualized with ImmPACT DAB Peroxidase Substrate (Vec-
tor). Slides were counterstained with hematoxylin.
Scoring of stained tissues. Slides were semiquantita-
tively scored in random order by researchers who were blinded
with regard to disease. CD68 staining was scored as follows:
05 no cells, 15,20 cells, 25 21–50 cells, 35 51–99 cells,
45 100–199 cells, and 55.200 cells per section. IL-18 and
TNF staining was scored as follows: 05 0% of section,
15,10% of section, 25 10–25% of section, and 35.25% of
section. IL-33 staining was scored both according to the per-
centage of IL-33–positive vasa vasorum per section and accord-
ing to the number of IL-33–positive ECs per vasa vasorum.
Soluble autoantibody and cytokine receptor detec-
tion. All serum samples were collected prior to CABG, after a
minimum of 4 hours of fasting. Enzyme-linked immunosorbent
assay, using appropriately diluted serum according to the
instructions of the manufacturer, was performed to assay titers
of soluble ST2 (R&D Systems) and anti–cyclic citrullinated
peptide 2 (anti–CCP-2; Axis-Shield). A BN Systems N Latex
RF kit (Siemens) was used to determine rheumatoid factor
(RF) levels in serum samples.
Statistical analysis. GraphPad Prism and SPSS soft-
ware were used for all statistical analyses. The chi-square test
and Fisher’s exact test (for categorical variables), the t-test for
independent samples (for continuous normally distributed var-
iables), and the Mann-Whitney U test (for continuous variables
without normal distribution) were used to identify significant
differences between RA and non-RA patients. Correlations
were determined using Spearman’s rho. P values less than 0.05
were considered significant, and all tests were 2-sided.
RESULTS
Macrophage detection and IL-18 and TNF
expression in aortic adventitia. The proportion of aor-
tic adventitia biopsy specimens in which CD681 macro-
phages were detectable (63% of RA specimens and 56%
of non-RA specimens) and the number of CD681 cells
per section (Figure 1A) were similar in CVD patients
with RA and those without RA (additional information
is available upon request from the corresponding
author). TNF was expressed in 63% of biopsy specimens
from RA patients compared with 30% of specimens
from non-RA patients (P5 0.04). In contrast, IL-18 was
present in all biopsy specimens, suggesting ubiquitous
expression in the aortic vascular tissue lesion (additional
information is available upon request from the corre-
Figure 1. Macrophage, interleukin-18 (IL-18), and tumor necrosis
factor (TNF) evaluation in the aortic adventitia of late-stage cardio-
vascular disease (CVD) patients with (n5 19) and those without
(n5 20) rheumatoid arthritis (RA). CD681 macrophages (A), IL-18
(B), and TNF (C) were evaluated immunohistologically, and the
results were scored as described in Patients and Methods. Data are
shown as box plots. Each box represents the 25th to 75th percentiles.
Lines inside the boxes represent the median. Lines outside the boxes
represent the 5th and 95th percentiles. *5P , 0.05.
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sponding author). Crucially, although no difference in
the number of macrophages between RA and non-RA
patients was observed (Figure 1A), the absolute level of
IL-18 and TNF expression in aortic adventitia was higher
in RA patients (Figures 1B and C) compared with non-
RA controls (P5 0.03 and P5 0.02, respectively).
Neither the number of macrophages nor the level
of IL-18 or TNF expression correlated with hypertension
or smoking (additional information is available upon
request from the corresponding author). Furthermore,
the expression of IL-8 and TNF did not correlate with
several markers of CVD severity, including the number
of coronary arteries with significant stenosis, New York
Heart Association (NYHA) class (10), or the number of
previous myocardial infarctions. However, in RA pa-
tients, the left ventricular ejection fraction (as assessed
by ventriculography) was negatively correlated with IL-
18 levels (r520.569, P5 0.03) and the macrophage
number (r520.587, P5 0.05). In RA patients, neither
the macrophage number nor cytokine expression corre-
lated with several markers of disease severity, disease
activity (i.e., the Disease Activity Score in 28 joints [11],
tender joint count, erythrocyte sedimentation rate, CRP,
RF, or anti–CCP-2 level), or disease duration.
IL-33 in ECs within aortic adventitia. IL-33
was detected in the majority of aortic adventitia biopsy
specimens from both RA patients (88%) and non-RA
patients (72%) but was restricted to the nucleus of vasa
vasorum ECs (additional information is available upon
request from the corresponding author). The proportion
of vasa vasora expressing IL-33 (IL-331 vasa vasorum)
was higher in RA patients compared with non-RA
patients (mean6 SEM 20.46 15.8% versus 8.66 9.5%;
P5 0.02) (Figure 2A). The proportion of EC nuclei pos-
itive for IL-33 within each vasa vasorum (IL-331 ECs)
was also substantially greater in RA patients compared
with non-RA patients (mean 6 SEM 58.7 6 34.1% ver-
sus 32.9 6 28.5%; P 5 0.02) (Figure 2B). In the internal
thoracic artery, the proportion of IL-331 vasa vasorum
was similar in RA patients (89%) and non-RA patients
(79%), but RA patients had a higher proportion of
IL-331 ECs (30.6 6 26.3% versus 13.1 6 12.5%; P 5
0.04). The proportions of IL-331 ECs and IL-331 vasa
vasorum in aortic adventitia did not correlate with any tra-
ditional CV risk factors (additional information is avail-
able upon request from the corresponding author). In RA
patients, the proportion of IL-331 ECs in aortic adventitia
was significantly correlated with NYHA functional class
(r5 0.618, P5 0.018) but not with other markers of CVD
severity. Furthermore, the proportion of IL-331 ECs in
the aortic adventitia of RA patients was also significantly
correlated with the tender joint count (r 5 0.582, P 5
0.023) (data not shown) and the swollen joint count (r 5
0.619, P5 0.014) (Figure 2C).
Interpretation of the functional implications of
circulating IL-33 expression generally requires parallel
evaluation of soluble ST2. Even though we observed
nuclear IL-33 expression only in ECs and not extracellu-
larly, we evaluated soluble ST2 levels in serum and
observed significantly higher levels in RA patients com-
pared with non-RA patients (mean6 SEM 158.56 52
pg/ml versus 12.796 13 pg/ml; P 5 0.002) (Figure 2D).
The level of soluble ST2 did not correlate with vascular
IL-33 expression or other RA clinical and immunologic
parameters; however, it did correlate with IL-18 expres-
sion (r5 0.582, P5 0.02) and the CRP level (r5 0.745,
P5 0.001).
DISCUSSION
Our novel study demonstrates a significant alter-
ation in the aortic adventitia cytokine microenvironment
Figure 2. IL-33 and soluble ST2 (sST2) in late-stage CVD patients
with (n5 19) and those without (n5 20) RA. A and B, Immunohis-
tologic evaluation and quantification of the percentage of vasa vaso-
rum (VV) in the aortic adventitia (AA) that were positive for IL-33
(A) and the percentage of IL-33–positive endothelial cells (ECs) in
each vasa vasorum (B). Data are shown as box plots. Each box rep-
resents the 25th to 75th percentiles. Lines inside the boxes represent
the median. Lines outside the boxes represent the 5th and 95th per-
centiles. C, Correlation between swollen joint counts and the per-
centage of IL-33–positive ECs in each vasa vasorum. D, Serum levels
of soluble ST2. Values are the mean6 SEM. *5P , 0.05;
***5P5 0.002. See Figure 1 for other definitions.
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in CAD patients with RA compared with those without
RA. Our data suggest that the underlying pathology in
the vessel is different not only at a local level (i.e., ECs
of microvessels within aortic adventitia) but also
systemically within other macrovessels (i.e., internal tho-
racic artery). We observed that compared with non-RA
controls, RA patients have significantly higher expres-
sion of the proinflammatory cytokines IL-18 and TNF in
aortic adventitia, higher expression of nuclear IL-33 in
ECs of vasa vasorum in aortic adventitia, and higher lev-
els of soluble ST2.
Although most studies have focused on the
expression of circulating IL-33, previous studies showed
that IL-33 was expressed in human vascular ECs (3,12),
and this may be of great importance. Intracellular/nucle-
ar full-length IL-33, which is thought to act as an alarmin
when it is released by necrotic cells (13), is a transcrip-
tion factor (14). As a transcription factor, endothelial
IL-33 can induce NF-kB signaling, with subsequent EC
activation (i.e., up-regulation of vascular cell adhesion
molecule [VCAM] and intercellular adhesion molecule
[ICAM]) (15). Thus, the vasa vasora of RA patients with
increased nuclear IL-33 are likely to be more predis-
posed to EC activation, leading to increased adhesion
and infiltration of inflammatory cells, which again will
increase IL-33 expression.
This is further supported by the fact that TNF
(which was increased in aortic adventitia in our RA
cohort) is known to stimulate ECs, with a consequent
up-regulation of ICAM and VCAM via an intracellular
IL-33–dependent signal (15). The increased IL-33
expression within microvascular ECs of RA patients
might therefore represent a stromal alteration, which
could contribute to increased CVD risk in RA. Further-
more, it is known that TNF, similar to other proinflam-
matory cytokines, increases secretion of soluble ST2 by
numerous cell types (16). Thus, although soluble ST2
may counteract circulating IL-33 activity, the high sys-
temic levels of soluble ST2 in RA could reflect enhanced
inflammation, which is supported by the observed corre-
lation with the CRP level. Moreover, the correlation
between soluble ST2 and aortic adventitia IL-18 expres-
sion is also pertinent given that increased IL-18 expres-
sion exacerbates atherosclerosis (17), while IL-18
deficiency reduces atherosclerosis (18).
Collectively, our data suggest that in RA patients,
the adventitial microenvironment, characterized by
higher levels of IL-18 and TNF and higher expression of
nuclear IL-33 within microvascular ECs, together with
increased levels of soluble ST2, amplify the proathero-
genic nature of the vessel, which theoretically enhances
the pathology of atherosclerosis.
Based on the observed increased number of
IL-331 ECs within both the aortic adventitia and the
internal thoracic artery of RA patients, one might specu-
late that this phenomenon could lead to a generalized
endothelial dysfunction and impairment of microvascular
function, which is likely to contribute to both RA-
specific manifestations (such as synovitis and extraarticu-
lar manifestations) and the pathogenesis of ischemia
(due to both macrovascular and microvascular disease)
and heart failure. In theory, the observed positive associa-
tion between IL-331 ECs and NYHA class may reflect,
among other factors, increased ischemia in patients in
whom the expression of IL-33 in ECs is increased, causing
microvascular cardiac disease (which is known to frequent-
ly occur in RA). It should also be noted that although the
luminal endothelium has been the main focus of studies
and theories to explain aspects of the pathogenesis of ath-
erosclerosis, our studies suggest that the endothelium cov-
ering vasa vasorum (which provides the oxygen and
nutrition supply to the macrovessel) may also play a crucial
role in the development of atherosclerosis.
Of note, the number of macrophages and the lev-
el of IL-18 expression in the aortic adventitia were
inversely correlated with the left ventricular ejection
fraction. The cause of this finding is unclear, and
although it could be the result of a Type II error, it could
reveal an important clinical relationship. For example,
aortic inflammation might reflect systemic inflammation,
which might contribute to the development of heart fail-
ure. Moreover, it is possible that aortic inflammation
mirrors a more generalized vascular inflammation,
including the coronary arteries (and small intramural
cardiac arteries), which leads to myocardial ischemia
and consequent ischemia-related heart failure.
The current study has several possible limitations,
which include a relatively small sample size. Hence, the
lack of some associations and differences may be caused
by Type II errors. However, compared with other biopsy
studies, this study is relatively large and does provide justi-
fication for larger, more in-depth studies. This is also a
cross-sectional study, and therefore no cause-and-effect
relationships can be identified. However, it should be
noted that this study is the first to examine the aortic
adventitia microenvironment in RA and non-RA patients
and thus provides valuable information about vascular
biology. Moreover, an additional advantage is that the cur-
rent study did not rely on autopsy samples, which are sus-
ceptible to deterioration postmortem, but instead difficult-
to-obtain fresh surgical specimens were used.
In summary, our data suggest that not only sys-
temic inflammation but also vascular inflammation may
play a role in the pathogenesis of CVD and of accelerated
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CVD in RA, with IL-33 and related cytokines being
potentially important players. These findings may help to
explain why antirheumatic therapies, including anti-TNF
treatment, decrease the risk of CVD (7). In theory, these
therapies may reduce the CV risk not only due to an effect
on systemic inflammation but also due to a direct effect
on the vasculature: both on inflammation in plaques, and
on adventitial inflammation, which is suspected to be
involved in both atheroma formation and destabilization.
These results therefore emphasize the necessity for future
studies that examine the influence of the vascular cytokine
environment in RA on CVD outcome.
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